<?xml version='1.0' encoding='utf-8'?>
<document id="12534646"><sentence text="Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers."><entity charOffset="36-46" id="DDI-PubMed.12534646.s1.e0" text="amprenavir" /><entity charOffset="51-62" id="DDI-PubMed.12534646.s1.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s1.e0" e2="DDI-PubMed.12534646.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s1.e0" e2="DDI-PubMed.12534646.s1.e1" /></sentence><sentence text="To evaluate the safety and the pharmacokinetic interaction between amprenavir and delavirdine after multiple dose administration in healthy volunteers"><entity charOffset="67-77" id="DDI-PubMed.12534646.s2.e0" text="amprenavir" /><entity charOffset="82-93" id="DDI-PubMed.12534646.s2.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s2.e0" e2="DDI-PubMed.12534646.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s2.e0" e2="DDI-PubMed.12534646.s2.e1" /></sentence><sentence text="" /><sentence text="This was a prospective, open-label, randomized, controlled, two-sequence, two-period multiple dose study with 18 healthy subjects" /><sentence text=" Volunteers were randomly assigned to amprenavir, 600 mg twice a day, or delavirdine, 600 mg twice a day, for 10 days, followed by both drugs for another 10 days with pharmacokinetic evaluation on day 10 and day 20"><entity charOffset="38-48" id="DDI-PubMed.12534646.s5.e0" text="amprenavir" /><entity charOffset="73-84" id="DDI-PubMed.12534646.s5.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s5.e0" e2="DDI-PubMed.12534646.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s5.e0" e2="DDI-PubMed.12534646.s5.e1" /></sentence><sentence text=" Adverse events were recorded throughout the study" /><sentence text="" /><sentence text="Amprenavir decreased all the delavirdine pharmacokinetic parameters apart from tmax"><entity charOffset="0-10" id="DDI-PubMed.12534646.s8.e0" text="Amprenavir" /><entity charOffset="29-40" id="DDI-PubMed.12534646.s8.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s8.e0" e2="DDI-PubMed.12534646.s8.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s8.e0" e2="DDI-PubMed.12534646.s8.e1" /></sentence><sentence text=" Delavirdine C12h dropped from 7,916 to 933 ng ml-1 (median decrease 5,930 ng ml-1, 95% CI 3,013, 8,955 ng ml-1)"><entity charOffset="1-12" id="DDI-PubMed.12534646.s9.e0" text="Delavirdine" /></sentence><sentence text=" A decrease in amprenavir t(1/2) was also seen leading to almost identical median amprenavir C24h values" /><sentence text=" No serious clinical adverse events were observed during the study" /><sentence text=" The most frequently reported effects were gastrointestinal symptoms, headache, fatigue and rash" /><sentence text="" /><sentence text="Amprenavir is an effective inducer of delavirdine metabolism, probably through its effect on hepatic CYP3A4"><entity charOffset="0-10" id="DDI-PubMed.12534646.s14.e0" text="Amprenavir" /><entity charOffset="38-49" id="DDI-PubMed.12534646.s14.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s14.e0" e2="DDI-PubMed.12534646.s14.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s14.e0" e2="DDI-PubMed.12534646.s14.e1" /></sentence><sentence text=" This could have consequences in other drug-drug interaction situations" /><sentence text=" Delavirdine is an inhibitor of amprenavir metabolism"><entity charOffset="1-12" id="DDI-PubMed.12534646.s16.e0" text="Delavirdine" /><entity charOffset="32-42" id="DDI-PubMed.12534646.s16.e1" text="amprenavir" /><pair ddi="false" e1="DDI-PubMed.12534646.s16.e0" e2="DDI-PubMed.12534646.s16.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s16.e0" e2="DDI-PubMed.12534646.s16.e1" /></sentence><sentence text=" The regimen of amprenavir 600 mg and delavirdine 600 mg twice a day is not recommended when an antiretroviral effect from delavirdine is required"><entity charOffset="16-26" id="DDI-PubMed.12534646.s17.e0" text="amprenavir" /><entity charOffset="38-49" id="DDI-PubMed.12534646.s17.e1" text="delavirdine" /><entity charOffset="123-134" id="DDI-PubMed.12534646.s17.e2" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.12534646.s17.e0" e2="DDI-PubMed.12534646.s17.e0" /><pair ddi="false" e1="DDI-PubMed.12534646.s17.e0" e2="DDI-PubMed.12534646.s17.e1" /><pair ddi="false" e1="DDI-PubMed.12534646.s17.e0" e2="DDI-PubMed.12534646.s17.e2" /><pair ddi="false" e1="DDI-PubMed.12534646.s17.e1" e2="DDI-PubMed.12534646.s17.e1" /><pair ddi="false" e1="DDI-PubMed.12534646.s17.e1" e2="DDI-PubMed.12534646.s17.e2" /></sentence><sentence text="" /></document>